Baseline demographics and clinical characteristics of patients in the CIMON study
| . | Treated patients (N = 21) . |
|---|---|
| Sex, n (%) | |
| Male | 16 (76) |
| Female | 5 (24) |
| Age at inclusion, y | |
| Median (range) | 62 (22-77) |
| Body mass index at inclusion, kg/m2 | |
| Median (range) | 23.9 (16.7-33.1) |
| Leukemia risk category (ELN 2022), n (%) | |
| Favorable | 7 (33) |
| Intermediate | 6 (29) |
| Adverse | 8 (38) |
| Karyotype, n (%) | |
| Normal | 10 (48) |
| Abnormal | 11 (52) |
| Induction chemotherapy, n (%) | |
| Cytarabine + anthracycline | 20 (95) |
| Azacitidine + venetoclax | 1 (5) |
| Consolidation chemotherapy, n (%) | |
| Cytarabine | 14 (67) |
| Cytarabine + anthracycline | 3 (15) |
| Daunorubicin | 1 (5) |
| Azacitidine + venetoclax | 1 (5) |
| None | 1 (5) |
| Unknown (premature discontinuation) | 1 (5) |
| Patients who received antibiotics∗ during IC, n (%) | |
| Yes | 19 (90) |
| No | 2 (10) |
| Patients who received antibiotics during consolidation chemotherapy, n (%) | |
| Therapeutic antibiotics | 10 (48) |
| Prophylactic antibiotics | 3 (14) |
| No systemic antibiotics | 7 (33) |
| Unknown (premature discontinuation) | 1 (5) |
| . | Treated patients (N = 21) . |
|---|---|
| Sex, n (%) | |
| Male | 16 (76) |
| Female | 5 (24) |
| Age at inclusion, y | |
| Median (range) | 62 (22-77) |
| Body mass index at inclusion, kg/m2 | |
| Median (range) | 23.9 (16.7-33.1) |
| Leukemia risk category (ELN 2022), n (%) | |
| Favorable | 7 (33) |
| Intermediate | 6 (29) |
| Adverse | 8 (38) |
| Karyotype, n (%) | |
| Normal | 10 (48) |
| Abnormal | 11 (52) |
| Induction chemotherapy, n (%) | |
| Cytarabine + anthracycline | 20 (95) |
| Azacitidine + venetoclax | 1 (5) |
| Consolidation chemotherapy, n (%) | |
| Cytarabine | 14 (67) |
| Cytarabine + anthracycline | 3 (15) |
| Daunorubicin | 1 (5) |
| Azacitidine + venetoclax | 1 (5) |
| None | 1 (5) |
| Unknown (premature discontinuation) | 1 (5) |
| Patients who received antibiotics∗ during IC, n (%) | |
| Yes | 19 (90) |
| No | 2 (10) |
| Patients who received antibiotics during consolidation chemotherapy, n (%) | |
| Therapeutic antibiotics | 10 (48) |
| Prophylactic antibiotics | 3 (14) |
| No systemic antibiotics | 7 (33) |
| Unknown (premature discontinuation) | 1 (5) |
ELN, European Leukemia Network.
Piperacillin-tazobactam and/or carbapenem and/or third-generation cephalosporins.